AIM ImmunoTech Inc. announced the release of its latest CEO Corner segment on July 07, 2026, highlighting continued momentum in its pancreatic cancer program. Chief Executive Officer Thomas Equels discussed significant clinical, strategic, and operational milestones positioning the company's lead product, Ampligen, for its next stage of development. The announcement underscores the company's focus on addressing the urgent unmet need in late-stage pancreatic cancer treatment.

DURIPANC Phase 2 Program Progress

In the segment, Mr. Equels reviewed recent advancements in the DURIPANC Phase 2 clinical program. This study evaluates Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab). Key milestones discussed include the successful completion of patient enrollment and dosing in the study. The company reported encouraging interim clinical observations and continued favorable safety findings.

Strategic Collaborations and Future Planning

The CEO outlined ongoing Phase 3 planning activities, indicating a transition toward pivotal-stage development. Strategic collaborations with AstraZeneca and Erasmus Medical Center were emphasized as critical drivers for the program. Additionally, the segment detailed the expansion of AIM ImmunoTech's intellectual property portfolio.

Ampligen's Broader Potential

Mr. Equels addressed the broader potential of Ampligen to help overcome resistance in immunologically "cold" tumors. The company believes it is entering one of the most catalyst-rich periods in its history. The CEO Corner segment is available on the company's website for stakeholders seeking detailed insights into the clinical and operational strategy.

AIM ImmunoTech Inc. has completed the dosing phase for the final subject in its Phase 2 DURIPANC clinical trial, evaluating Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer. This milestone positions the company for a potential pivotal Phase 3 program, with primary endpoint analysis anticipated to begin in December 2026 and topline results expected in Q1 2027. The study is a collaboration involving AIM, AstraZeneca, and Erasmus Medical Center.

The trial's primary endpoint is the Clinical Benefit Rate (CBR), defined as the proportion of patients achieving stable disease, partial response, or complete response at 24 weeks. Secondary endpoint analysis, including Overall Survival (OS) and progression-free survival, is expected to begin in June 2027. This data aims to identify 'super-responder' patient subsets likely to benefit most from Ampligen-based therapy, informing the design of a potential Phase 3 study.

Clinical Foundation and Historical Data

The DURIPANC study builds upon a previous Named Patient Program where Ampligen was used as a monotherapy in late-stage pancreatic cancer. Historical data from that program indicated survival improvements based on specific biomarker stratifications, as shown below:

Strategic Milestones and Outlook

AIM Chief Executive Officer Thomas K. Equels emphasized the company's focus on utilizing exploratory biomarker data to design a Phase 3 study. The company has reported positive interim updates, a favorable safety profile with no significant toxicity, and maintained orphan drug designation for pancreatic cancer in major markets. Additionally, AIM has strengthened its balance sheet and regained compliance with NYSE American continued listing standards.

Management believes the program represents a significant opportunity to create shareholder value, particularly as the biotechnology sector values late-stage oncology assets. With completed enrollment, strengthened intellectual property protection, and ongoing regulatory planning, AIM views the upcoming period as a critical value-inflection point for the Ampligen franchise.